Skip to main content

Month: April 2021

Kyber Data Science Launches Next-Gen Health Care Data Platform for Institutional Investors

NEW YORK, April 26, 2021 (GLOBE NEWSWIRE) — Institutional investors can now readily access the most diverse and granular source of real-world health care data available, enabling faster and more profitable decisions. Kyber Data Science (“Kyber”), a subsidiary of Cowen Inc. (NASDAQ: COWN) (“Cowen”), today unveiled a next-generation user experience to disentangle and simplify complex health care data and provide visibility into the specific market influences that drive performance. Kyber Data Science is the first in its industry to enrich real-world health care data exclusively for the investment community. Its new dashboard allows investors to track utilization of health care treatments, even in pharmaceutical and biopharmaceuticals markets that have long been “information voids,” such as injectables and infusions, diagnostics, procedures...

Continue reading

Identity and Access Management Provider BIO-key Issued U.S. Patent for Enabling Next-Generation Continuous Biometric User Authentication

Expands IP Portfolio to 18 IAM and Biometric Patents,Underscoring BIO-key’s Long-Term Commitment to Innovation WALL, N.J., April 26, 2021 (GLOBE NEWSWIRE) — BIO-key International, Inc. (NASDAQ: BKYI), an innovative provider of identity and access management (IAM) solutions powered by biometrics, announced that the company has been issued patent # 10,984,085 by the U.S. Patent and Trademark Office for its invention titled “Biometric Recognition for Uncontrolled Acquisition Environments.” The patent will protect BIO-key’s method of enabling next-generation continuous and passive biometric user experiences with its process for enrollment and continuous authentication. The patent expands BIO-key’s portfolio to a total of 18 IAM and biometric patents. The patent provides an important asset for the company to leverage for its own authentication...

Continue reading

Water Ways’ Strawberry Irrigation Project in Ethiopia Expands to CAD$470,000

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, April 26, 2021 (GLOBE NEWSWIRE) — Water Ways Technologies Inc. (TSXV: WWT) (“Water Ways” or the “Company“), is pleased to announce that the CAD $330,000 strawberry irrigation project in Ethiopia (previously announced on March 18, 2021) has expanded to a value of approximately CAD$470,000. The strawberry irrigation project covers an area of 20 hectares of greenhouses, using Israeli drip irrigation technology. Water Ways signed the agreements with a wholly owned subsidiary of Midroc Ethiopia Investment Group, one of the largest investment companies operating in Ethiopia following successful implementation of projects previously signed with the group in 2020 (See press release dated September 9, 2020). The expansion...

Continue reading

HIGHCO : Transactions sur Actions propres du 19/04/21 au 23/04/21

Déclaration des transactions sur actions propresRéalisées du 19 au 23 avril 2021 Paris, le 26 avril 2021 Présentation agrégée par jour et par marchéNom de l’émetteur Code identifiant émetteur Jour de la transaction Code identifiant de l’instrument financier Volume total journalier(en nombre d’actions) Prix pondéré moyen journalier d’acquisition des actions MarchéHIGH CO 969500FYLNRXCJ348W66 22/04/2021 FR 0000054231 1 000 5,57 € XPARHIGH CO 969500FYLNRXCJ348W66 23/04/2021 FR 0000054231 1 000 5,72 € XPARPrésentation détaillée transaction par transactionCode identifiant PSI JourHeure de la transaction Code identifiant de l’instrument financier Prix unitaire (unité) Devise Quantité achetée Code identifiant marché Numéro de référence de la transaction Objectif du rachat969500UEQ3U3P21QNJ13 2021-04-2207:06:55 FR 0000054231 5,5 EUR 105 XPAR jAj6AftZk7000WF0 couverture...

Continue reading

Avenir LNG announces the first bunkering of the Avenir Accolade by its sister ship the Avenir Advantage

Avenir LNG (NOTC: AVENIR) today announced that it has successfully completed the bunkering of the Avenir Accolade by its sister ship the Avenir Accolade in Pasir Gudang, Pengerang, Malaysia on 26 April 2021. Both ships built by Keppel Offshore & Marine’s Nantong Shipyard are 7,500 cbm, dual purpose, LNG supply and bunkering vessels (LBV). The Avenir Accolade undertook the operation whilst passing through Malaysia on its maiden voyage to deliver the commissioning cargo to Avenir’s HIGAS LNG terminal in Sardinia. Peter Mackey, CEO Avenir LNG Limited, commented: “We’re thrilled to see the Avenir Advantage alongside the Avenir Accolade, the first time they are back together since leaving the shipyard in Nantong. We look forward to welcoming the Avenir Accolade to our HIGAS terminal in Sardinia in a few weeks’ time with the commissioning...

Continue reading

Dyadic International veranstaltet Kamingespräch mit dem Titel „The Potential of the Transformative Dyadic C1 Protein Technology in Helping Meet Global Health Challenges“

JUPITER, Fla., April 26, 2021 (GLOBE NEWSWIRE) — Dyadic International, Inc. („Dyadic“, „wir“, „uns“, „unser“ oder das „Unternehmen“) (NASDAQ:DYAI), ein globales Biotechnologieunternehmen, das sich auf die Entwicklung und den Einsatz seiner proprietären C1-Zellen-Protein-Produktionsplattform konzentriert, mit der die Entwicklung von Impfstoffen, Therapeutika und anderen proteinbasierten Produkten optimiert werden soll, hat heute bekanntgegeben, dass es am Dienstag, den 4. Mai 2021, um 16:00 Uhr CEST ein Kamingespräch organisiert. Hauptthema des Kamingesprächs wird das Potenzial der transformativen C1-Proteintechnologie von Dyadic zur Bewältigung globaler gesundheitlicher Herausforderungen sein. Die moderierte Diskussion umfasst die folgenden Key Opinion Leaders (KOLs):Alain Townsend, Ph.D. – Weatherall Institute – Oxford University Albert...

Continue reading

Dyadic International, ‘변형 Dyadic C1 단백질 기술이 글로벌 보건 과제를 해결에 기여할 잠재력’ 주제로 파이어사이드 챗 개최

미국 플로리다주 주피터, April 26, 2021 (GLOBE NEWSWIRE) — 글로벌 바이오테크 기업인 Dyadic International, Inc. (NASDAQ: DYAI)은 2021년 5월 4일 오전 10시(미국동부시간) 파이어사이드 챗(fireside chat) 행사를 실시한다고 밝혔다. Dyadic International은 자체 개발한 C1-cell 단백질 생산 플랫폼의 적용, 공급을 통해 백신과 치료제 및 기타 단백질 기반 제품 개발을 촉진하는 데 중점을 두고 있다. 파이어사이드 챗은 변형 Dyadic C1 단백질 기술이 글로벌 보건 과제를 해결하는 데 도움을 줄 잠재력을 다룰 예정이다. 사회자를 두고 진행되는 이번 좌담에는 핵심 오피니언 리더(KOL)들이 참여한다:Alain Townsend, Ph.D. – Weatherall Institute – 옥스퍼드대 Albert Osterhaus, P.V.M, Ph.D. – 에라스무스대병원 Cecil Nick – Parexel (임상 및 규제 지원 담당) Joris Vandeputte – 생물의약품 표준화 국제연합좌담 주제는 다음과 같다:C1 플랫폼의 규제 고려 사항과 장점 다른 생산 플랫폼과 관련해 슈말렌베르그 바이러스와 리프트밸리열 바이러스용 고가치 항원의 성공적인 생산에 대한 사례 연구 Dyadic의 SARS-CoV-2 수용체 결합영역 백신 후보인 DYAI-100의 개발 진행, 이미 알려진 변이 및 신종 변이 발현을 위한 C1 세포주 급속 엔지니어링 등 SARS-CoV-2 변이에 대응하기 위한 Dyadic의 노력 코로나19 다가백신, 그리고 대부분의...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.